Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from NovaBay Pharma ( (NBY) ).
On January 29, 2026, NovaBay’s board adopted a 2026 Equity Incentive Plan, approved by stockholders on March 12, 2026, authorizing more than 22 million shares for a broad array of stock-based awards to employees, directors, and advisors. On March 31, 2026, the compensation committee granted large, heavily performance-based RSU and PSU packages to CEO Michael Kazley and RSUs to CFO Tommy Law, with vesting rules and severance-linked acceleration designed to align executive pay with stock performance and digital asset value, and to support leadership retention.
Also on March 31, 2026, NovaBay entered new employment agreements with Kazley and Law that fix base salaries at $200,000 from 2027 for the CEO and immediately for the CFO, introduce market-based future bonus and equity opportunities, and provide tiered severance and change-of-control protections in exchange for non-compete and non-solicit covenants. In a parallel governance shift, the board approved an April 2, 2026 legal name change to Stablecoin Development Corporation, with trading under the SDEV ticker expected to begin April 6, 2026, signaling a strategic repositioning while formally leaving stockholder rights intact.
The most recent analyst rating on (NBY) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on NovaBay Pharma stock, see the NBY Stock Forecast page.
Spark’s Take on NBY Stock
According to Spark, TipRanks’ AI Analyst, NBY is a Neutral.
The score is primarily held down by severely deteriorated financial performance (revenue collapse to $0, continued losses, negative cash flow, and deeply negative equity). Technical indicators also remain bearish with price far below major moving averages and negative MACD. Corporate events provide some potential upside via new financing and a strategic pivot, but they also raise dilution and crypto-related risk, and valuation support is limited due to ongoing losses and no dividend.
To see Spark’s full report on NBY stock, click here.
More about NovaBay Pharma
NovaBay Pharmaceuticals, Inc., which is changing its corporate name to Stablecoin Development Corporation and ticker to SDEV, is transitioning away from its legacy pharmaceutical branding toward a focus that includes digital assets, as reflected in new performance metrics tied to digital asset net asset value. The company is listed in Delaware and is updating its charter and bylaws solely to reflect this name change, which does not alter existing stockholder rights.
Average Trading Volume: 540,104
Technical Sentiment Signal: Strong Sell
Current Market Cap: $39.67M
For a thorough assessment of NBY stock, go to TipRanks’ Stock Analysis page.